Elapegademase

Elapegademase, (brand name Revcovi), is a medication for the treatment of the rare disease adenosine deaminase deficiency-SCID in children and adults.

Elapegademase-lvlr
Clinical data
Trade namesRevcovi
Other nameselapegademase-lvlr
AHFS/Drugs.comMonograph
License data
Routes of
administration		intramuscular
Legal status
Legal status
Identifiers
CAS Number
KEGG

Elapegademase is a recombinant enzyme.[1] It is administered weekly by intramuscular injection.[2]

Elapegademase may interact with PEGylated drugs.[2]

Elapegademase was approved by the FDA in 2018. Leadiant Biosciences was awarded a priority review voucher for its development under the pediatric rare diseases program.[3]

References
  1. "Elapegademase: Drug Information". www.uptodate.com. Retrieved 28 March 2019.
  2. "LexiComp: Elapegademase-lvlr". LexiComp. Retrieved 28 March 2019.
  3. "Elapegademase - Leadiant Biosciences - AdisInsight". adisinsight.springer.com. Retrieved 28 March 2019.
  • "Elapegademase". Drug Information Portal. U.S. National Library of Medicine.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.